AI Summary & Key Takeaways
AI InsightPatient who had stage IIA (T2N0M0) breast cancer was treated with adjuvant tamoxifen and was followed for one year without any evidence disease.
📌 3 Key Takeaways
Abstract
Male breast cancer constitutes 1% of all breast cancers and 0.2% of all cancers in males. Incidence of bilateral breast cancer in males is less than 2%. Here, a male patient with metachronous bilateral breast cancer diagnosed 23 years after the treatment of the primary tumor is reported regarding his diagnosis, treatment, and prognosis. 76 year-old male patient was treated with radical mastectomy and stage I (T1N0M0) breast cancer was detected and patient was followed without any adjuvant treatment. During follow-up, a second primary tumor was diagnosed in the contralateral breast and modified radical mastectomy was performed. Patient who had stage IIA (T2N0M0) breast cancer was treated with adjuvant tamoxifen and was followed for one year without any evidence disease.
Özet
Erkeklerde meme kanseri tüm meme kanserli hastaların yaklaşık %1'ini ve erkeklerde görülen kanserlerin %0.2'sini oluşturur. Erkeklerde saptanan meme kanserinin bilateral olma olasılığı ise %2'den daha azdır. Burada, 23 yıl sonra saptanan metakron bilateral meme kanseri tanısı ile tedavi edilmiş bir erkek hasta tanı, tedavi ve prognoz yönünden incelenerek bildirilmiştir. 76 yaşında erkek hastaya meme kanseri tanısı konularak sol radikal mastektomi uygulanmış ve evre I (T1N0M0) hastalık saptanması nedeniyle adjuvan tedavisiz izleme alınmıştır. İzlem sırasında karşı memede ikinci primer tümör saptanan hastaya modifiye radikal mastektomi uygulandı. Evre IIA (T2N0M0) meme kanseri olarak sınıflandırılan hastaya adjuvan tamoksifen tedavisi verildi ve bir yıldır hastalıksız olarak takip edilmektedir.